FLT3 and leukemia: FLT3 is widely overexpressed in patients with acute myeloid leukemia (AML), and its mutations lead to the constitutive activation of downstream signals.100,101 Internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in ~25% of AML patients, and point mutations in the tyrosine kinase domain (TKD) are observed in 7–10% of patients.102 These mutations have been identified to be involved in the occurrence of leukemia.